GB9711990D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB9711990D0
GB9711990D0 GB9711990A GB9711990A GB9711990D0 GB 9711990 D0 GB9711990 D0 GB 9711990D0 GB 9711990 A GB9711990 A GB 9711990A GB 9711990 A GB9711990 A GB 9711990A GB 9711990 D0 GB9711990 D0 GB 9711990D0
Authority
GB
Grant status
Grant
Patent type
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9711990A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/38Medical treatment of vector-borne diseases characterised by the agent
    • Y02A50/408Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa
    • Y02A50/411Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria
    • Y02A50/412Medical treatment of vector-borne diseases characterised by the agent the vector-borne disease being caused by a protozoa of the genus Plasmodium, i.e. Malaria the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
GB9711990A 1997-06-11 1997-06-11 Vaccine Pending GB9711990D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9711990A GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB9711990A GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine
PCT/EP1998/003479 WO1998056414A1 (en) 1997-06-11 1998-06-03 Oil in water vaccine compositions
CA 2293444 CA2293444A1 (en) 1997-06-11 1998-06-03 Oil in water vaccine compositions
EP19980933600 EP0999852A1 (en) 1997-06-11 1998-06-03 Oil in water vaccine compositions
JP50158899A JP2002504106A (en) 1997-06-11 1998-06-03 Oil-in-water vaccine composition
CN 98806134 CN1260723A (en) 1997-06-11 1998-06-03 Oil in water vaccine composition
KR19997011655A KR20010013644A (en) 1997-06-11 1998-06-03 Oil in water vaccine compositions

Publications (1)

Publication Number Publication Date
GB9711990D0 true GB9711990D0 (en) 1997-08-06

Family

ID=10813866

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9711990A Pending GB9711990D0 (en) 1997-06-11 1997-06-11 Vaccine

Country Status (7)

Country Link
EP (1) EP0999852A1 (en)
JP (1) JP2002504106A (en)
KR (1) KR20010013644A (en)
CN (1) CN1260723A (en)
CA (1) CA2293444A1 (en)
GB (1) GB9711990D0 (en)
WO (1) WO1998056414A1 (en)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
US8221761B1 (en) * 1999-02-26 2012-07-17 Novartis Ag Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing CG motifs
ES2228497T3 (en) 1999-04-19 2005-04-16 Glaxosmithkline Biologicals S.A. adjuvant composition comprising saponin and an immunostimulatory oligonucleotide.
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
DK1889630T3 (en) 2000-10-18 2012-03-05 Glaxosmithkline Biolog Sa Vaccines comprising the MAGE-antigen coupled to protein D fragment
CA2767116A1 (en) * 1999-05-13 2000-11-23 Wyeth Holdings Corporation Adjuvant combination formulations
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US8017590B1 (en) 1999-10-22 2011-09-13 Sanofi Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
DE60124899D1 (en) 2000-05-10 2007-01-11 Sanofi Pasteur Ltd By mage mini gene encoded immunogenic polypeptide and its uses
CA2448208C (en) * 2001-05-30 2011-11-29 Uwe Eichhorn Influenza vaccine composition
CN1555253A (en) * 2001-09-13 2004-12-15 韩国科学技术研究院 Oily composition of taxol,preparation for chemical therapeutic embolism and their producing method
US20050250175A1 (en) * 2002-08-02 2005-11-10 Takehiko Nomura Bacterial cell wall skeleton component preparaion
ES2594758T3 (en) 2002-10-23 2016-12-22 Glaxosmithkline Biologicals S.A. Vaccination procedures against malaria
JP2008500984A (en) 2004-05-28 2008-01-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Vaccine composition comprising virosomes and a saponin adjuvant
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
JP5770414B2 (en) 2005-03-23 2015-08-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム New composition
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP3020411A1 (en) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
JP2009531387A (en) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
JP5639760B2 (en) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Influenza vaccine
JP5592110B2 (en) 2006-07-18 2014-09-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Malaria vaccine
WO2008012538A3 (en) 2006-07-25 2008-06-05 Secr Defence Live vaccine strains of francisella
EP2468300B1 (en) 2006-09-26 2017-12-20 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US9452209B2 (en) 2007-04-20 2016-09-27 Glaxosmithkline Biologicals Sa Influenza vaccine
CA2668405C (en) 2006-11-03 2015-05-05 Schering-Plough Ltd. Canine lyme disease vaccine
US20100055166A1 (en) 2007-03-02 2010-03-04 Gerald Hermann Voss Novel method and compositions
CN101784282B (en) 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
JP5508266B2 (en) 2007-08-13 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
EP2227483B1 (en) 2007-12-19 2017-04-19 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Soluble forms of hendra and nipah virus f glycoprotein and uses thereof
EP2293813A4 (en) 2008-05-23 2012-07-11 Univ Michigan Nanoemulsion vaccines
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
JP5722782B2 (en) 2008-09-26 2015-05-27 ナノバイオ コーポレーション Nanoemulsion therapeutic compositions and methods of use thereof
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
WO2010141861A1 (en) 2009-06-05 2010-12-09 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
WO2010148111A1 (en) 2009-06-16 2010-12-23 The Regents Of The University Of Michigan Nanoemulsion vaccines
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
DE102009056883B4 (en) * 2009-12-03 2012-08-16 Novartis Ag Vaccine adjuvants and to improved processes for the preparation thereof
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
GB201003920D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment
KR20130063493A (en) 2010-03-26 2013-06-14 글락소스미스클라인 바이오로지칼즈 에스.에이. Hiv vaccine
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
JP2014501225A (en) 2010-09-27 2014-01-20 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
EP2694099A1 (en) 2011-04-08 2014-02-12 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
JP6152107B2 (en) 2011-09-16 2017-06-21 ユセベ ファルマ ソシエテ アノニム Neutralizing antibodies against the major exotoxin TcdA and TcdB of Clostridium difficile
WO2013074501A1 (en) 2011-11-14 2013-05-23 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
ES2673556T3 (en) 2012-05-16 2018-06-22 Immune Design Corp. Vaccines for HSV-2
CA2874923A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
EP2877208A1 (en) 2012-07-24 2015-06-03 Sanofi Pasteur Vaccine compositions
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US20160280763A1 (en) 2013-11-01 2016-09-29 University Of Oslo Albumin variants and uses thereof
WO2015071769A3 (en) 2013-11-13 2015-11-12 University Of Oslo Outer membrane vesicles and uses thereof
EP3069138A2 (en) 2013-11-15 2016-09-21 Oslo Universitetssykehus HF Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
US20160287696A1 (en) 2013-11-20 2016-10-06 La Jolla Institute For Allergy And Immunology Pan pollen immunogens and methods and uses for immune response modulation
WO2015077442A3 (en) 2013-11-20 2015-11-12 La Jolla Institute For Allergy And Immunology Grass pollen immunogens and methods and uses thereof for immune response modulation
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
KR20160105813A (en) 2014-01-21 2016-09-07 이뮨 디자인 코포레이션 Compositions for use in the treatment of allergic conditions
WO2015131053A1 (en) 2014-02-28 2015-09-03 Alk-Abelló A/S Polypeptides derived from phl p and methods and uses thereof for immune response modulation
KR101696514B1 (en) * 2014-08-18 2017-01-24 서울대학교산학협력단 Temperature Sensitive Mycobacterial strain and its use as vaccine against mycobacterial infection disease
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
CA3011887A1 (en) 2016-03-14 2017-09-21 Stian FOSS Engineered immunoglobulins with altered fcrn binding
WO2017221072A3 (en) 2016-06-21 2018-03-15 University Of Oslo Hla binding vaccine moieties and uses thereof
WO2018037045A1 (en) 2016-08-23 2018-03-01 Glaxosmithkline Biologicals Sa Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date Type
CA2293444A1 (en) 1998-12-17 application
EP0999852A1 (en) 2000-05-17 application
JP2002504106A (en) 2002-02-05 application
CN1260723A (en) 2000-07-19 application
KR20010013644A (en) 2001-02-26 application
WO1998056414A1 (en) 1998-12-17 application

Similar Documents

Publication Publication Date Title
GB9807805D0 (en) Vaccine
GB9820956D0 (en) Vaccine
GB9703543D0 (en) Vaso-belt
GB9526438D0 (en) Vaccine component
GB9526433D0 (en) Vaccine component
GB9708841D0 (en) Holding means
GB9706774D0 (en) Hovertrain concept
GB9822425D0 (en) Suit
GB9719796D0 (en) Medicament
GB9726234D0 (en) Medicament
GB9715177D0 (en) Medicament
GB0002424D0 (en) Medicament
GB9702946D0 (en) Medicament
GB9622439D0 (en) Vaccine composition
GB9622437D0 (en) Vaccine composition
GB9622438D0 (en) Vaccine composition
GB9623233D0 (en) Vaccine composition
GB9616351D0 (en) Vaccine composition
GB9701489D0 (en) Antigen
EP1023083A4 (en) Veterinary vaccines
GB9716727D0 (en) Crutch
GB9701888D0 (en) Novel methods
GB9722697D0 (en) Experiment preparation unit
GB9703307D0 (en) Novel use
GB9713471D0 (en) Novel use